Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order ...

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate the complexities of a product launch.

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate resources effectively. In 2025, staying ahead of these changes will be vital ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...

Managing third-party risk is one of the most arduous challenges facing pharmaceutical companies, and regulatory requirements are just one piece of this puzzle. Pharmaceutical organizations are ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the ...